Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California.
To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.
Banerjee
Ritu
R
Division of Pediatric Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA. Banerjee.ritu@mayo.edu
Allen
Jennifer
J
Lin
S-Y Grace
SY
Westenhouse
Janice
J
Desmond
Ed
E
Schecter
Gisela F
GF
Scott
Cheryl
C
Raftery
Ann
A
Mase
Sundari
S
Watt
James P
JP
Flood
Jennifer
J
D000328:Adult; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D002140:California; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification*; D012189:Retrospective Studies; D013997:Time Factors; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000382:microbiology*
D000995:Antitubercular Agents